Cornell University

Ten Oaks Group Welcomes Bennett Cook and Alex Ney as Operating Partners

Retrieved on: 
Mercoledì, Maggio 1, 2024

CHARLOTTE, N.C., May 1, 2024 /PRNewswire/ -- Ten Oaks Group, a leading family office specializing in corporate carve-outs, is excited to announce the appointment of Bennett Cook and Alex Ney as Operating Partners.

Key Points: 
  • CHARLOTTE, N.C., May 1, 2024 /PRNewswire/ -- Ten Oaks Group, a leading family office specializing in corporate carve-outs, is excited to announce the appointment of Bennett Cook and Alex Ney as Operating Partners.
  • Alex Ney brings a strong background in financial advisory and operational improvement to Ten Oaks Group.
  • "We are delighted to welcome Bennett and Alex to the Ten Oaks team," said Curtis Griner, Managing Partner at Ten Oaks Group.
  • The addition of Bennett Cook and Alex Ney as Operating Partners underscores Ten Oaks Group's commitment to strengthening its operational capabilities and driving the value creation process at the company's portfolio companies.

U.S. Energy Development Corporation Promotes Robert Thaxton to VP of Oil and Gas Business Operations

Retrieved on: 
Martedì, Aprile 30, 2024

FORT WORTH, Texas, April 30, 2024 /PRNewswire/ -- U.S. Energy Development Corporation (U.S. Energy), an exploration and production (E&P) company focused on the development of energy projects throughout North America, has announced that Robert Thaxton has been promoted from senior strategist to the organization's Vice President of Oil and Gas Business Operations.

Key Points: 
  • FORT WORTH, Texas, April 30, 2024 /PRNewswire/ -- U.S. Energy Development Corporation (U.S. Energy), an exploration and production (E&P) company focused on the development of energy projects throughout North America, has announced that Robert Thaxton has been promoted from senior strategist to the organization's Vice President of Oil and Gas Business Operations.
  • In this elevated role, Thaxton will oversee interdepartmental initiatives to improve productivity and streamline operations.
  • "We are extremely proud to welcome Robert Thaxton to our leadership team," said Jordan Jayson , chairman and CEO of U.S. Energy.
  • "Over the years, Robert has repeatedly demonstrated his commitment to U.S. Energy by taking on additional responsibilities and leading vital initiatives.

Hyster-Yale Group provides students with real-world AI experience in 2024 Kellogg Design Challenge

Retrieved on: 
Giovedì, Maggio 2, 2024

GREENVILLE, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Representatives from Hyster-Yale Group joined Northwestern faculty from the Kellogg School of Management and Segal Institute for Design Innovation and innovation industry leaders like IDEO, PwC and IA Collaborative to facilitate the 2024 Kellogg Design Challenge, the largest business design case competition across MBA programs globally.

Key Points: 
  • GREENVILLE, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Representatives from Hyster-Yale Group joined Northwestern faculty from the Kellogg School of Management and Segal Institute for Design Innovation and innovation industry leaders like IDEO, PwC and IA Collaborative to facilitate the 2024 Kellogg Design Challenge, the largest business design case competition across MBA programs globally.
  • “As we pursue that mission, the Kellogg Design Challenge is an outstanding opportunity to tap into some of the brightest young minds.
  • “We want to thank the Kellogg Design Challenge team, and the graduate students from reputed universities for their outstanding engagement in making the Kellogg Design Challenge an incredible success,” says Dr. Gopi Samayajula, Senior Vice President of Global Product Development, Hyster-Yale.
  • In addition to the Kellogg Design Challenge, Hyster-Yale has several longstanding collaborations with academic and career development programs across the country.

Gaxos Health Expands Medical Advisory Board

Retrieved on: 
Giovedì, Aprile 25, 2024

Roseland, NJ, April 25, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that Gaxos Health has expanded its Medical Advisory Board with the appointment of Dr. Eric Margolis and Dr. Jeff Pavell.

Key Points: 
  • Roseland, NJ, April 25, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that Gaxos Health has expanded its Medical Advisory Board with the appointment of Dr. Eric Margolis and Dr. Jeff Pavell.
  • “The addition of top medical talent to our Medical Advisory Board reflects our continued commitment to pursuing a best-in-class solution for Gaxos Health,” said Vadim Mats, CEO of Gaxos.AI.
  • “An advisory board of experts in their respective fields will allow to create a better product and advancing our mission of creating value for shareholders.”
    Dr. Eric Margolis, M.D.
  • “We welcome Dr. Margolis and Dr. Pavell to the advisory board as their experience and insight will allow us to create a more fine-tuned solution,” Vadim Mats added.

BriaCell Announces Oral and Poster Presentations at ASCO 2024

Retrieved on: 
Mercoledì, Aprile 24, 2024

Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD

Key Points: 
  • Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD
    Two poster presentations include Drs.
  • Principal Investigator and Professor of Oncology, Mayo Clinic, Saranya Chumsri, MD, will be giving the presentation.
  • BriaCell will also have two poster presentations.
  • The first poster will describe the Company’s ongoing pivotal Phase 3 registrational study in advanced metastatic breast cancer.

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Retrieved on: 
Lunedì, Aprile 22, 2024

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company, today announced an in-license agreement with Cornell University to expedite development of the investigational gene therapy candidate LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy.

Key Points: 
  • Under the license agreement, Lexeo has acquired certain rights1 including rights to current and future data generated in an ongoing investigator-initiated Phase 1A trial of AAVrh.10hFXN to treat FA cardiomyopathy ( NCT05302271 ).
  • The agreement will support Lexeo’s efforts to develop a potentially life-changing therapy for this unmet need.
  • Lexeo previously licensed know-how relating to AAVrh.10hFXN from Weill Cornell Medicine and collaborated with researchers there to further study the candidate, which Lexeo refers to as LX2006.
  • “This agreement with Lexeo Therapeutics builds upon years of collaboration between Weill Cornell Medicine and Lexeo to benefit patients with FA cardiomyopathy.

Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients

Retrieved on: 
Giovedì, Aprile 18, 2024

By targeting Bcl-2 at the mRNA level rather than the protein, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.

Key Points: 
  • By targeting Bcl-2 at the mRNA level rather than the protein, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.
  • The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administered over twenty-eight days.
  • The Phase 1b portion of the study is expected to commence after completion of BP1002 monotherapy cohorts and will assess the safety and efficacy of BP1002 in combination with decitabine in refractory/relapsed AML patients.
  • Gail J. Roboz, M.D., is the National Principal Investigator for the Phase 1/1b trial.

Heavy hitter infrastructure lawyer Patrick Harder joins Norton Rose Fulbright in Los Angeles

Retrieved on: 
Martedì, Aprile 16, 2024

Los Angeles, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Global law firm Norton Rose Fulbright announced today that preeminent infrastructure and public-private partnerships (P3) lawyer Patrick Harder has joined its Los Angeles office.

Key Points: 
  • Los Angeles, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Global law firm Norton Rose Fulbright announced today that preeminent infrastructure and public-private partnerships (P3) lawyer Patrick Harder has joined its Los Angeles office.
  • He will also be North America Co-Head of Infrastructure with Doug Fried and Canada Head of Infrastructure Jay LeMoine .
  • What drew me to Norton Rose Fulbright was its global platform and network of  leading infrastructure lawyers, and its commitment to creating meaningful contributions to address the global infrastructure deficit.
  • Norton Rose Fulbright has more than 3000 lawyers across 53 global cities and has one of the most extensive P3 practices in the world.

Kaplan Educational Foundation Honors Danielle Conley and Harold Elish for Commitment to Equity and Opportunity

Retrieved on: 
Mercoledì, Maggio 1, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240501978493/en/
    Kaplan Educational Foundation 2024 Leadership Award honorees Danielle Conley & Harold Elish (Photo: Business Wire)
    Ms. Conley and Mr. Elish will accept the Leadership Awards at the Foundation’s annual benefit on May 15th in New York City.
  • The Award recognizes a demonstrated commitment to increasing opportunity and equity for individuals who have been overlooked and underserved, in education and beyond.
  • She has significant experience conducting sensitive internal investigations on issues pertaining to racial and gender equity.
  • Mr. Elish joined the Board of the Kaplan Educational Foundation in 2014, becoming the first person unaffiliated with Kaplan to serve.

Knowles Reports Q1 2024 Financial Results and Provides Outlook for Q2 2024

Retrieved on: 
Mercoledì, Maggio 1, 2024

Non-GAAP information should be considered a supplement to, and not a substitute for, financial statements prepared in accordance with GAAP.

Key Points: 
  • Non-GAAP information should be considered a supplement to, and not a substitute for, financial statements prepared in accordance with GAAP.
  • In addition, the non-GAAP financial measures included in this press release do not have standard meanings and may vary from similarly titled non-GAAP financial measures used by other companies.
  • Knowles believes that its presentation of these non-GAAP financial measures is useful because it provides investors and securities analysts with the same information that Knowles uses internally for purposes of assessing its core operating performance.
  • For a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures, see the reconciliation table accompanying this release.